SOURCE: DNAPrint Genomics, Inc.

April 04, 2007 07:00 ET

DNAPrint™ Genomics' Advancements in PT-401 and Statinome Presented at Clinical Pharmacology Conference

SARASOTA, FL -- (MARKET WIRE) -- April 4, 2007 -- DNAPrint™ Genomics, Inc. (OTCBB: DNAG) today reported that several advancements in its proprietary DNA research on PT-401 and Statinome formed the basis for three papers that were presented by DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., and Neil Kabrun, Ph.D., a senior scientist with the DNAPrint Computational Biology Group, at the recent annual meeting of the American Society for Clinical Pharmacology and Therapeutics held in Anaheim, Calif.

"Presenting papers at conventions is an important part of the research process, because it gives one's peers in the scientific community a chance to review and comment on work that is being done, which ultimately may lead to its acceptance as sound science," Dr. Gomez said. "Presenting these specific papers at the meeting of the Society for Clinical Pharmacology and Therapeutics is an important step in advancing DNAPrint's research agenda and brings us closer to the day when DNAPrint products based on PT-401 and Statinome may be introduced to the marketplace."

In one study, PT-401 was shown to be more potent and longer acting than epoetin alfa, a form of recombinant human erythropoietin currently in the market for the treatment of anemia. In another study, EPOFusion™, DNAPrint's proprietary, pre-clinical computer model for testing the characteristics and mechanisms of EP-401, was successfully used to predict a patient's responses to epoetin alfa, and will be used to predict a patient's response to PT-401. All PT-401 experiments will be first run through the computer using the EPOFUSION model, thus facilitating the preparation of clinical protocols and increasing its possibilities of succeeding during the clinical development of PT-401 in patients with anemia.

A third paper detailed the discovery of genetic variations that form the basis of Statinome, a predictive diagnostic test that will allow the physician to select an alternative therapy that would avoid statin-induced muscle effects in patients.

PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used for the treatment of anemia. PT-401 is a potential competitor in the EPO market that currently exceeds $10 billion and is rapidly growing.

Statinome is a protocol that can be used to detect the possibility of myalgia, or severe muscle pain, in patients who take statins, which are drugs that are used to lower cholesterol. Myalgia may also lead to rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side effect.

About DNAPrint™ Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941-366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848